Compare · DXCM vs EMBC
DXCM vs EMBC
Side-by-side comparison of DexCom Inc. (DXCM) and Embecta Corp. (EMBC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and EMBC operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $29.58B, about 153.4x EMBC ($192.8M).
- Over the past year, DXCM is down 8.6% and EMBC is down 66.8% - DXCM leads by 58.2 points.
- DXCM has hit the wire 6 times in the past 4 weeks while EMBC has been quiet.
- DXCM has more recent analyst coverage (25 ratings vs 9 for EMBC).
- Company
- DexCom Inc.
- Embecta Corp.
- Price
- $76.65-1.74%
- $3.25-3.13%
- Market cap
- $29.58B
- $192.8M
- 1M return
- +4.76%
- +4.67%
- 1Y return
- -8.64%
- -66.84%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- News (4w)
- 6
- 0
- Recent ratings
- 25
- 9
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Embecta Corp.
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.
Latest DXCM
- EVP Chief Legal Compliance Off Brown Michael Jon sold $126,514 worth of shares (1,700 units at $74.42) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 104,653 units (SEC Form 4)
- Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes
- Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time
- Executive Chair Sayer Kevin R sold $1,926,432 worth of shares (26,756 units at $72.00) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 355,726 units (SEC Form 4)
- Dexcom Further Advances Vision of Glucose Biosensing for All
- Deutsche Bank initiated coverage on Dexcom with a new price target
- EVP Chief Legal Compliance Off Brown Michael Jon sold $128,435 worth of shares (1,700 units at $75.55) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 106,353 units (SEC Form 4)
- Director Foletta Mark G sold $296,540 worth of shares (4,000 units at $74.13) as part of a pre-agreed trading plan (SEC Form 4)
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
Latest EMBC
- embecta appoints Nimish Muzumdar as SVP and President, North America
- Marvell Technology and Flex Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
- VP, Chief Accounting Officer Roth Anthony M. was granted 30,000 shares, increasing direct ownership by 61% to 78,833 units (SEC Form 4)
- embecta to Participate in Investor Events
- Amendment: SEC Form SCHEDULE 13G/A filed by Embecta Corp.
- SEC Form SD filed by Embecta Corp.
- Embecta Corp. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits
- embecta Completes Acquisition of Owen Mumford Holdings Limited
- embecta to Participate at the 2026 BofA Securities Global Health Care Conference
- Embecta Corp. downgraded by BTIG Research